MorphicLogo.jpg
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
July 09, 2021 06:35 ET | Morphic Therapeutic
MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset...
MorphicLogo.jpg
Morphic Therapeutic to Host Analyst and Investor Call on July 9, 2021
July 02, 2021 09:00 ET | Morphic Therapeutic
WALTHAM, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO’21 Virtual Congress
May 28, 2021 08:00 ET | Morphic Therapeutic
Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies All dosing regimens...
MorphicLogo.jpg
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare Conference
May 28, 2021 07:30 ET | Morphic Therapeutic
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and First Quarter 2021 Financial Results
April 29, 2021 08:00 ET | Morphic Therapeutic
Expanded research and development collaboration with Janssen for third integrin program Announced positive preliminary results from Phase 1 SAD clinical trial of MORF-057 Received acceptance to...
MorphicLogo.jpg
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of Directors
April 28, 2021 16:01 ET | Morphic Therapeutic
WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to...
MorphicLogo.jpg
Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 08:00 ET | Morphic Therapeutic
First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...
MorphicLogo.jpg
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public Offering
March 02, 2021 20:25 ET | Morphic Therapeutic
WALTHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
MorphicLogo.jpg
Morphic Therapeutic Announces Proposed Public Offering
March 01, 2021 16:01 ET | Morphic Therapeutic
WALTHAM, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of...
MorphicLogo.jpg
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
March 01, 2021 07:00 ET | Morphic Therapeutic
MORF-057 well tolerated in all dose cohorts MORF-057 achieved greater than 95% mean receptor occupancy of α4β7 integrin at three highest dose levels; demonstrates ability to saturate α4β7 receptor ...